Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Video Expert Opinion
Colleague Insights
Living Resources
Conferences
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Bladder Cancer and
1 other channel

Expert Opinion / Commentary · December 07, 2020

2020 Top Stories in Bladder Cancer: Switch-Maintenance Avelumab Following First-Line Platinum-Based Chemotherapy—A New Paradigm in Advanced Urothelial Carcinoma

Guru Sonpavde MD

 

 Save  Recommend
 Share

Additional Info

  1. Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218-1230.
  2. Alva A, Csőszi T, Ozguroglu M, et al. Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Ann Oncol. 2020;31(suppl 4):LBA23.
  3. Powles T, van der Heijden MS, Castellano D, et al; DANUBE study investigators. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020 Sep 21. doi:10.1016/S1470-2045(20)30541-6. Online ahead of print.
  4. Opdivo (nivolumab) significantly improves disease free-survival vs. placebo as adjuvant therapy for patients with high-risk, muscle-invasive urothelial carcinoma in phase 3 CheckMate -274 trial. News release. September 24, 2020. Accessed November 20, 2020.
  5. Study of nivolumab in combination with ipilimumab or standard of care chemotherapy compared to the standard of care chemotherapy alone in treatment of participants with untreated inoperable or metastatic urothelial cancer (CheckMate901). ClinicalTrials.gov. Updated October 8, 2020. Accessed November 20, 2020.
  6. Enfortumab vedotin and pembrolizumab vs. chemotherapy alone in untreated locally advanced or metastatic urothelial cancer (EV-302). ClinicalTrials.gov. Updated November 16, 2020. Accessed November 20, 2020.

Disclosure statements are available on the authors' profiles:

Guru Sonpavde MD

Further Reading

Recently Updated